Back to search results

Family HOPE Study: Improving Genetic Testing for Cancer Risk

This study, called the Family HOPE Study, is looking at better ways to share genetic test results with family members who might also be at risk for cancer. About 15% of cancers are inherited, meaning they run in families due to changes in certain genes. Many people don't know they have these gene changes, which can prevent them from getting important healthcare. This study wants to see if having a healthcare provider help communicate these genetic results to at-risk relatives can increase the number of people who get genetic counseling and testing. You might be able to join if you are an adult cancer patient treated at City of Hope, have a specific gene change linked to cancer, and are willing to share contact information for your first-degree relatives (like parents, siblings, or children). The study will measure how many of your relatives get tested within 9 months.

Study design
This is an interventional study with 240 participants. Participants will be randomly assigned to one of two groups.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured up to 9 months after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05772130

Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study

Recruiting
NAAges 18+InterventionalHealth services
City of Hope Medical Center
~240 participants
Updated 2026-01-05 on ClinicalTrials.gov
What's tested:Best PracticeElectronic Health Record ReviewPersonal ContactSurvey Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The percentage of uptake of cascade testing among patients' first-degree at-risk relatives
Measured over Up to 9 months after enrollment

Conditions

Hematopoietic and Lymphoid System Neoplasm
Hereditary Malignant Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematopoietic and Lymphatic System NeoplasmHereditary Malignant NeoplasmMalignant Solid NeoplasmGermline Variation

NCT05772130

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope Medical Center

    Duarte, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Stacy W Gray · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Stacy W. Gray
[email protected]
626-218-8662
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

PATIENTS: Enrolled in City of Hope (COH) institutional review board (IRB) 07047 or have been seen by COH Genetics for genetic testing
PATIENTS: Have an pathogenic/ likely pathogenic germline variant
PATIENTS: Fluent in English
PATIENTS: Age \>= 18 years
PATIENTS: Willing to provide contact information for eligible first-degree relatives
PATIENTS: \>= 2 first-degree relatives that are eligible for genetic testing and reside in the United States of America
FIRST-DEGREE RELATIVES: Proband is a COH patient and has consented to this study
FIRST-DEGREE RELATIVES: First-degree relative of proband
FIRST-DEGREE RELATIVES: Resides within the United States
FIRST-DEGREE RELATIVES: Has not undergone genetic testing for the known familial variant
FIRST-DEGREE RELATIVES: Are fluent in English
FIRST-DEGREE RELATIVES: Age \>= 18 years

Exclusion

PATIENTS: Unable to provide informed consent
PATIENTS: =\< 2 at-risk first-degree relatives who are eligible for genetic testing and/or reside within the United States
PATIENTS: Unwilling to provide contact information for family members
FIRST-DEGREE RELATIVES: Unable or unwilling to provide informed consent
FIRST-DEGREE RELATIVES: Have undergone genetic testing for the known familial variant
FIRST-DEGREE RELATIVES: Resides outside of the United States

What this trial measures

  • The percentage of uptake of cascade testing among patients' first-degree at-risk relativesUp to 9 months after enrollment

    Will calculate descriptive statistics first, including the mean, median and standard deviation of the number of the first-degree and secondary-degree at-risk relatives. We will then compare the proportion of identified relatives who completed genetic testing between the intervention and the control arms with a one-sided Cochran-Mantel-Haenszel test. Type I error of 0.05 will be used and descriptive statistics will be calculated for all exploratory outcomes along with 95% confidence intervals. All statistical testing and calculation of confidence intervals will adjust for intra-proband correlation.